Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9657–9661 | Cite as

Clinical significance of GRHL3 expression in diffuse large B cell lymphoma

  • Wei Liu
  • Minwen Ha
  • Xiaodong Wang
  • Nanchang Yin
Original Article

Abstract

In the present study, we assessed the GRHL3 expression in 967 patients with diffuse large B cell lymphomas to identify the potential prognostic value and the development of specific therapeutic strategies. All patients enrolled were from a previous study by Hao Zhang et al. (BMC Cancer 14:333, 2014). GRHL3 expression status was evaluated by immunohistochemical analysis. Survival analysis using the Kaplan–Meier method and multivariate analysis were conducted to adjust the effect of GRHL3 expression as a potential independent prognostic factor. In the enrolled 967 patients, GRHL3 expression was detected in 398 (41.16 %) patients under immunohistochemical analysis. The 5-year survival rate in patients with GRHL3 expression was significantly lower than that in those without GRHL3 expression (37.8 vs 52.8 %, P < 0.001). Multivariate analysis identified GRHL3 expression as an independent predictor of poor survival. The sensitivity and specificity of GRHL3 for the diagnosis of germinal center B cell (GCB)/non-GCB was 89.2 % (182/204) and 82.1 % (174/212), respectively. GRHL3 expression may be useful as a prognostic factor and for the diagnosis GCB/non-GCB of diffuse large B cell lymphoma.

Keywords

Diffuse large B cell lymphomas Survival GRHL3 

Abbreviations

BM

Bone marrow

CR

Complete remission

DLBCL

Diffuse large B cell lymphoma

HLA

Human leukocyte antigen

PBS

Phosphate-buffered saline

GCB

Germinal center B cell

Notes

Acknowledgments

We would like to express our gratitude to Hao Zhang et al. for their help of clinical pathology records and statistical analysis.

Authors’ contributions

WL and NY carried out the experiment and drafted the manuscript. MH participated in the design of the study and performed the statistical analysis. XW conceived the study, participated in its design and coordination, and helped to draft the manuscript. All the authors read and approved the final manuscript.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer Press; 2008.Google Scholar
  2. 2.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedGoogle Scholar
  3. 3.
    Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999;111:S8–12.PubMedGoogle Scholar
  4. 4.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Hermine O, Haioun C, Lepage E, d’Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–72.PubMedGoogle Scholar
  7. 7.
    Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996;14:2131–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–51.PubMedGoogle Scholar
  9. 9.
    Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.PubMedGoogle Scholar
  10. 10.
    Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood. 1997;90:4078–91.PubMedGoogle Scholar
  11. 11.
    Darido C, Jane SM. Grhl3 and GEF19 in the front rho. Small GTPases Landes Biosci. 2010;1(2):104–7.CrossRefGoogle Scholar
  12. 12.
    Ting SB, Wilanowski T, Cerruti L, Zhao LL, Cunningham JM, Jane SM. The identification and characterization of human Sister-of-Mammalian Grainyhead (SOM) expands the grainyhead-like family of developmental transcription factors. Biochem J. 2003;370:953–62.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Peyrard-Janvid M, Leslie EJ, Kousa YA, Smith TL, Dunnwald M, Magnusson M, et al. Dominant mutations in GRHL3 cause Van der Woude Syndrome and disrupt oral periderm development. Am J Hum Genet. 2014;94(1):23–32.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yu Z, Lin KK, Bhandari A, Spencer JA, Xu X, Wang N, et al. The grainyhead-like epithelial transactivator Get-1/Grhl3 regulates epidermal terminal differentiation and interacts functionally with LMO4. Dev Biol. 2006;299:122–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Darido C, Georgy SR, Wilanowski T, Dworkin S, Auden A, Zhao Q, et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell. 2011;20:635–48.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wei Liu
    • 1
  • Minwen Ha
    • 1
  • Xiaodong Wang
    • 2
  • Nanchang Yin
    • 2
  1. 1.Department of Medical OncologyThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina
  2. 2.Department of Thoracic SurgeryThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina

Personalised recommendations